AstraZeneca Pharma India Limited
AstraZeneca Pharma India Limited, a biopharmaceutical company, manufactures, markets, and trades in pharmaceutical products in India and internationally. It provides medicines for cardiovascular, renal, metabolic, and immunological conditions; oncology medicines under the TAGRISSO, Lynparza, ENHERTU, IMFINZI, and Zoladex brand names; rare diseases medicines under the Koselugo brand name; and resp… Read more
AstraZeneca Pharma India Limited (ASTRAZEN) - Total Assets
Latest total assets as of September 2025: ₹16.15 Billion INR
Based on the latest financial reports, AstraZeneca Pharma India Limited (ASTRAZEN) holds total assets worth ₹16.15 Billion INR as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
AstraZeneca Pharma India Limited - Total Assets Trend (2005–2025)
This chart illustrates how AstraZeneca Pharma India Limited’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
AstraZeneca Pharma India Limited - Asset Composition Analysis
Current Asset Composition (March 2025)
AstraZeneca Pharma India Limited's total assets of ₹16.15 Billion consist of 88.4% current assets and 11.6% non-current assets.
| Asset Category | Amount (INR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₹5.09 Billion | 35.3% |
| Accounts Receivable | ₹1.85 Billion | 12.2% |
| Inventory | ₹5.49 Billion | 36.1% |
| Property, Plant & Equipment | ₹635.80 Million | 4.2% |
| Intangible Assets | ₹6.60 Million | 0.0% |
| Goodwill | ₹0.00 | 0.0% |
Asset Composition Trend (2005–2025)
This chart illustrates how AstraZeneca Pharma India Limited's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: AstraZeneca Pharma India Limited's current assets represent 88.4% of total assets in 2025, an increase from 79.8% in 2005.
- Cash Position: Cash and equivalents constituted 35.3% of total assets in 2025, up from 2.6% in 2005.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2005.
- Asset Diversification: The largest asset category is inventory at 36.1% of total assets.
AstraZeneca Pharma India Limited Competitors by Total Assets
Key competitors of AstraZeneca Pharma India Limited based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
|
USA | $67.26 Billion |
|
Kamada
NASDAQ:KMDA
|
USA | $378.79 Million |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
AstraZeneca Pharma India Limited - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Strong asset utilization - AstraZeneca Pharma India Limited generates 1.13x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Solid ROA - For every $100 in assets, AstraZeneca Pharma India Limited generates $7.62 in net profit.
AstraZeneca Pharma India Limited - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.87 | 2.25 | 1.86 |
| Quick Ratio | 0.87 | 1.44 | 1.21 |
| Cash Ratio | 0.51 | 1.05 | 0.00 |
| Working Capital | ₹6.78 Billion | ₹ 5.92 Billion | ₹ 2.58 Billion |
AstraZeneca Pharma India Limited - Advanced Valuation Insights
This section examines the relationship between AstraZeneca Pharma India Limited's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 27.12 |
| Latest Market Cap to Assets Ratio | 0.03 |
| Asset Growth Rate (YoY) | 40.8% |
| Total Assets | ₹15.18 Billion |
| Market Capitalization | $449.10 Million USD |
Valuation Analysis
Below Book Valuation: The market values AstraZeneca Pharma India Limited's assets below their book value (0.03 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: AstraZeneca Pharma India Limited's assets grew by 40.8% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for AstraZeneca Pharma India Limited (2005–2025)
The table below shows the annual total assets of AstraZeneca Pharma India Limited from 2005 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-03-31 | ₹15.18 Billion | +40.82% |
| 2024-03-31 | ₹10.78 Billion | +9.46% |
| 2023-03-31 | ₹9.85 Billion | +14.98% |
| 2022-03-31 | ₹8.57 Billion | +10.57% |
| 2021-03-31 | ₹7.75 Billion | +9.68% |
| 2020-03-31 | ₹7.06 Billion | +25.73% |
| 2019-03-31 | ₹5.62 Billion | +21.99% |
| 2018-03-31 | ₹4.61 Billion | +10.84% |
| 2017-03-31 | ₹4.15 Billion | -7.41% |
| 2016-03-31 | ₹4.49 Billion | +9.02% |
| 2015-03-31 | ₹4.12 Billion | -0.96% |
| 2014-03-31 | ₹4.16 Billion | +35.77% |
| 2013-03-31 | ₹3.06 Billion | -10.52% |
| 2012-03-31 | ₹3.42 Billion | +10.82% |
| 2011-03-31 | ₹3.09 Billion | +31.99% |
| 2010-03-31 | ₹2.34 Billion | -19.01% |
| 2009-03-31 | ₹2.89 Billion | +17.40% |
| 2008-03-31 | ₹2.46 Billion | +2.55% |
| 2007-03-31 | ₹2.40 Billion | +36.71% |
| 2006-03-31 | ₹1.75 Billion | +4.79% |
| 2005-03-31 | ₹1.67 Billion | -- |